FDA PDUFA Watch: Neurology Decisions to Track Through Late September

The FDA is expected to make six pivotal PDUFA decisions by late September affecting treatments and diagnostics in neurology, including Alzheimer disease imaging, Duchenne muscular dystrophy cardiomyopathy, Sanfilippo syndrome gene therapy, and Alexander disease antisense therapy, with key resubmissions and advisory committee votes adding regulatory complexity.

This Wire brief sits within Fusion42's coverage of Health.